What Next for SELLAS Life Sciences Group, Inc. (SLS) Stock After Making Yearly Low?

July 16, 2018 - By Ash Maslow

The stock of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) hit a new 52-week low and has $1.50 target or 9.00 % below today’s $1.65 share price. The 8 months bearish chart indicates high risk for the $29.99M company. The 1-year low was reported on Jul, 16 by Barchart.com. If the $1.50 price target is reached, the company will be worth $2.70M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 0.60% or $0.01 during the last trading session, reaching $1.65. About 418,100 shares traded or 68.02% up from the average. SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) has declined 71.31% since July 16, 2017 and is downtrending. It has underperformed by 83.88% the S&P500.

More notable recent SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares” on July 11, 2018, also Nasdaq.com with their article: “Mid-Morning Market Update: Markets Open Higher; Delta Air Lines Earnings Beat Estimates” published on July 12, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering” on July 13, 2018. More interesting news about SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) were released by: Streetinsider.com and their article: “SELLAS Life Sciences (SLS) Prices Upsized $24.2 Million Public Offering of Common Stock, Warrants” published on July 12, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut” with publication date: June 28, 2018.

SELLAS Life Sciences Group, Inc., a development-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company has market cap of $29.99 million. The company's lead product candidate is galinpepimut-S, a cancer immunotherapeutic agent for the treatment of hematologic cancers and solid tumor indications, including acute myeloid leukemia, malignant pleural mesothelioma, multiple myeloma, ovarian cancer, immune combo, and chronic myelogenous leukemia. It currently has negative earnings. It also develops NEUVAX, which is in Phase II clinical trial for the treatment of breast cancer; and Anagrelide controlled release, which has completed various clinical trials for the treatment of thrombocythemia.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.